WO2000027996A1 - Serum free medium for chondrocyte-like cells - Google Patents
Serum free medium for chondrocyte-like cells Download PDFInfo
- Publication number
- WO2000027996A1 WO2000027996A1 PCT/EP1999/008482 EP9908482W WO0027996A1 WO 2000027996 A1 WO2000027996 A1 WO 2000027996A1 EP 9908482 W EP9908482 W EP 9908482W WO 0027996 A1 WO0027996 A1 WO 0027996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serum free
- free medium
- medium
- serum
- fgf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Definitions
- Bone and cartilage transplantation is an absolute need in reconstruction of bone and cartilage segments in plastic surgery, traumatic surgery or after the removal of neoplastic lesions, etc.
- material of human (autologous, from donors or from cadavers) or animal origin has been used for this purpose.
- tissue transplantation the increased need for microbial safety in tissue transplantation, the advances in cell biology, cell differentiation and tissue engineering, the concept of rebuilding tissues from autologous or allogeneic cells expanded in vitro has become a growing field in the world of biomedical sciences.
- Cellular sources for skeletal repair include chondrocytes and cells committed to the chondrocyte lineage, and mesenchymal stem cells, the former specific for cartilage, the latter multipotential and therefore having the potential to be used to replace bone, cartilage and other tissues.
- Mesenchymal stem cells are found in bone marrow as well as in blood, dermis and periosteum. Although these cells are normally present at very low frequencies in bone marrow, these cells can be isolated purified and culturally expanded, for example, as described in U.S. Patent No. 5,486,359.
- chondrocytes and MSCs typically take place in culture medium supplemented with bovine serum or optimally with autologous serum from the patient.
- bovine serum or optimally with autologous serum from the patient.
- animal or autologous serum in chondrocyte and MSC cultures has certain disadvantages and limitations in view of the potential therapeutical applications of these cultures.
- serum is not the physiological fluid most cells closely contact in tissue in vivo. This is particularly true for chondrocytes that, in vivo, are embedded in their avascularized matrix and rely for their own growth and differentiation on various growth factors and cytokines acting in an autocrine/panacrine manner rather than diffusing from the distant bloodstream.
- serum substitutes for culturing cells for potential in vivo therapeutic applications is desirable.
- the present invention provides a serum substitute for culturing cells in vitro using well defined factors able to support cell viability, proliferation and differentiation as effectively as serum containing medium.
- the cells are articular chondrocytes or mesenchymal stem cells.
- the invention comprises a composition for the expansion of chondrocytes, comprising a minimum essential medium, a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, and insulin.
- the serum free growth medium for chondrocytes comprises FGF-2 as a growth factor, linoleic acid as the lipid/fatty acid source, ascorbic acid and ⁇ -mercaptoethanol as antioxidants, holo- and apo-transferrin as the iron source, and dexamethasone as a steroid.
- Optional ingredients can include cholesterol, trace metals such as selenium, and vitamins such as biotin and sodium pantotenate.
- the invention comprises a composition for the maintenance of mesenchymal stem cells, comprising a growth factor, albumin, a steroid, an antioxidant, an iron source, a fatty acid and/or a lipid source, one or more vitamins, one or more trace metals, and IGF-1 , in combination with a minimum essential medium.
- the serum free growth medium for mesenchymal stem cells comprises FGF-2, LIF and SCF as growth factors, sodium pantotenate and biotin as vitamins, and selenium as a trace metal.
- the present invention provides serum free compositions suitable for chondrocyte and mesenchymal stem cell growth and proliferation.
- the compositions may include in a base minimum essential medium, such as Coon's modified Ham's F-12 medium, the following components as a substitute for serum: i) one or more growth factors or proteins which cause resting cells to undergo cell division and/or differentiation, such as insulin, FGF-2, PDGFbb, EGF, LIF and SCF and IGF-1 ; ii) one or more steroids such as dexamethasone; iii) one or more sources of lipids and fatty acids, necessary for cell membrane biosynthesis, such as cholesterol and linoleic acid; and iv) an iron source such as transferrin.
- a base minimum essential medium such as Coon's modified Ham's F-12 medium
- the following components as a substitute for serum: i) one or more growth factors or proteins which cause resting cells to undergo cell division and/or differentiation, such as insulin, FGF-2, PDGF
- FGF-2, PDGFbb and EGF are potent mitogens for cells of mesenchymal origin.
- Dexamethasone is known to ' keep cells in a cycling phase in vitro.
- the serum free medium of the present invention may further comprise: i) albumin (preferably of mammalian species) which functions as an aspecific carrier; ii) one or more antioxidants such as ⁇ -mercaptoethanol; iii) a supplement for coenzyme transport in carboxyl group transfer reactions, such as biotin; iv) trace elements as a supplemental source of metal necessary for electron transport and many metalloenzymes and proteins, such as selenium; v) vitamins, such as biotin and pantotenate; and vi) ascorbic acid, to facilitate organization of the extracellular matrix.
- albumin preferably of mammalian species
- one or more antioxidants such as ⁇ -mercaptoethanol
- a supplement for coenzyme transport in carboxyl group transfer reactions such as biotin
- trace elements as a supplemental source of metal necessary for electron transport and many metalloenzymes and proteins, such as selenium
- vitamins such as biotin and pantotenate
- ascorbic acid to facilitate
- Insulin and dexamethasone are added at the average concentrations usually reported in the literature.
- IGF-I, LIF and SCF are present at concentrations in the range from about
- the defined components comprise EGF,
- FGFbb and FGF-2 ascorbic acid, linoleic acid, human serum albumin (HSA), ⁇ -mercaptoethanol, dexamethasone, insulin, human holo- and apo- transferrin.
- FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 1 to about 10 ng/ml. In a preferred embodiment, FGF-2, PDGFbb and EGF are present at concentrations of from
- the defined components comprise : EGF, PDGFbb and FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, ⁇ -mercaptoethan ⁇ l, dexamethasone, human holo- and apo- transferrin, selenium, biotin, sodium pantotenate.
- FGF-2, PDGFbb and EGF are present at concentrations in the range of from about 5 ng/ml to- about 10 ng/ml of each factor. The preferred concentrations of FGF-2, PDGFbb and EGF are 10 ng/ml.
- FGF-2 alone was found to be the most active factor for maintenance of osteochondrogenic potential in MSCs.
- Example 1 Articular cartilage was harvested from the knee joint of young adult human donors. The samples were first cleaned of any adherent muscular, connective or subchondral bone tissues, minced into l -3mm fragments and rinsed in PBS. Single chondrocytes were then released by repeated enzymatic digestions at 37°C with 0.25% trypsin, 400U/ml collagenase I, l OOOU/ml collagenase II and 1 mg/ml hyaluronidase. Trypsin was then blocked and removed by rapid and extensive washes in PBS containing soybean trypsin inhibitor.
- Cells were plated in anchorage-dependent conditions in Coon's modified Ham's F-12 medium supplemented either with 10% fetal calf serum (FCS, control culture) or the following defined components: EGF, PDGFbb and FGF-2, ascorbic acid, linoleic acid, human serum albumin (HSA), ⁇ - mercaptoethanol, dexamethasone, insulin, human holo- and apo-transferrin.
- FCS fetal calf serum
- Table 1 below shows the preferred amounts of each component.
- Insulin may not be substituted with IGF-1 in the medium for chondrocytes. Insulin was preferably at a concentration of 5 ⁇ g/ml.
- Bone marrow sample harvested from the iliac crest of the patient was washed twice with PBS.
- the nucleated cells were counted using methyl violet and plated at 5xl0 6 cells as unfractionated marrow per 10 cm tissue culture dish.
- the cells were maintained in Coon's modified Ham's F12 (F12) supplemented either with 10% FCS and 1 ng/ml
- FGF-2 control culture or the following defined components: EGF, PDGFbb,
- FGF-2 FGF-2, LIF, SCF, IGF-I, ascorbic acid, cholesterol, HSA, ⁇ -mercaptoethanol, dexamethasone, human holo- and apo-transferrin, selenium, biotin and sodium pantotenate.
- Table 2 shows the preferred amounts of each component.
- the cells were first plated for 48 hours in F12 medium supplemented with 10% human serum and 1 ng/ml FGF-2.
- FGF-2 alone was the most active factor for maintenance of osteochondrogenic potential in mesenchymal stem cells.
- Selenium, biotin and sodium pantotenate were preferably included for cell viability.
- LIF and SCF were seen to improve the extent of cell proliferation, in particular in combination with IGF-1.
- EGF/PDGF/FGF-2 1 - 10 ng/ml
- MTT Thiazolyl blue staining. Briefly, culture medium was removed and replaced with 0.5 ml of medium without supplement; then 25 ⁇ l MTT (Sigma,
- Example 4 The differentiation potential of the chondrocytes expanded in serum free conditions was tested both in vitro and in vivo.
- the expanded cells were transferred in anchorage-independent conditions and maintained as a pellet culture for 2-4 weeks in the serum free medium previously shown by Johnstone et al. (Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M. and Yoo, J.U. Exp. Cell Res. 238, 265-272, 1998) to induce chondrogenesis of serum expanded MSCs.
- the expanded cells were implanted for 2 to 8- weeks in athymic mice either as a dense cell suspension or after embeddment in fibrin gel (Tissucol).
- the samples were fixed in formalin, embedded in paraffin and sectioned. Serial sections were processed for histological (toluidine blue and alcian blue) analysis and immunohistochemistry with collagen-specific antibodies.
- FCS a total absence of full chondrogensis was observed both in vitro and in vivo; at most, a faint metachromatic staining was detected in some pellet cultures, but they always lacked well defined lacunae and well organized extracellular matrix.
- Example 5 The osteogenic potential of MSCs after expansion under serum free defined conditions was tested in vivo by implantation of the expanded cells in athymic mice after adsorption on collagraft.
- the medium contained Coon's modified Ham's F-12, dexamethasone, FGF-2, PDGFbb, EGF, transferrin, cholesterol, human serum albumin, biotin, selenium, Na pantotenate and ascorbic acid (concentrations as in Table 2).
- the combinations tested were 1) insulin; 2) IGF-1 ; 3) insulin and LIF; 4) insulin and SCF; 5) insulin, LIF and SCF; 6) IGF-1 and LIF; 7) IGF- 1 and SCF; and 8) IGF-1 , LIF and SCF.
- the samples were decalcified, included and processed for histology as above.
- the sections were stained with hematoxylin-eosin. All the conditions of expansion allowed the MSCs to reform bone tissue in vivo; however, the amount of bone formed varied from condition to condition.
- the combination of IGF-1 , LIF and SCF provided an optimal expansion environment among the combinations tested.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99971844A EP1131407B1 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte-like cells |
AU13804/00A AU758073B2 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte-like cells |
IL14291499A IL142914A0 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte-like cells |
CA002348687A CA2348687A1 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte-like cells |
US09/831,161 US6617159B1 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte cells |
JP2000581163A JP2002529071A (en) | 1998-11-09 | 1999-11-08 | Serum-free medium for chondrocyte-like cells |
DE69933579T DE69933579D1 (en) | 1998-11-09 | 1999-11-08 | SERUM-FREE MEDIUM FOR CHONDROCYTE-SIMILAR CELLS |
IL142914A IL142914A (en) | 1998-11-09 | 2001-05-01 | Serum free medium for chondrocyte-like cells |
US10/614,191 US7109032B2 (en) | 1998-11-09 | 2003-07-08 | Serum-free medium for mesenchymal stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10764698P | 1998-11-09 | 1998-11-09 | |
US60/107,646 | 1998-11-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09831161 A-371-Of-International | 1999-11-08 | ||
US10/614,191 Division US7109032B2 (en) | 1998-11-09 | 2003-07-08 | Serum-free medium for mesenchymal stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000027996A1 true WO2000027996A1 (en) | 2000-05-18 |
Family
ID=22317692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/008482 WO2000027996A1 (en) | 1998-11-09 | 1999-11-08 | Serum free medium for chondrocyte-like cells |
Country Status (10)
Country | Link |
---|---|
US (2) | US6617159B1 (en) |
EP (1) | EP1131407B1 (en) |
JP (1) | JP2002529071A (en) |
AT (1) | ATE342348T1 (en) |
AU (1) | AU758073B2 (en) |
CA (1) | CA2348687A1 (en) |
DE (1) | DE69933579D1 (en) |
IL (2) | IL142914A0 (en) |
RU (1) | RU2272839C2 (en) |
WO (1) | WO2000027996A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2828401A1 (en) * | 2001-08-10 | 2003-02-14 | Oreal | Cosmetic composition useful for improving skin condition comprises insulin-like growth of specific factor or it's mimetic and ascorbic acid |
JP2003052360A (en) * | 2001-08-20 | 2003-02-25 | Japan Science & Technology Corp | Method for culturing mesenchymal stem cell using extracellular substrate of basement membrane cell |
WO2003082305A1 (en) * | 2002-04-03 | 2003-10-09 | Naohide Yamashita | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells |
WO2004083415A1 (en) * | 2003-03-17 | 2004-09-30 | Biotissue Technologies Gmbh | Cartilaginous cell culture medium and the use thereof |
EP1478734A2 (en) * | 2002-01-25 | 2004-11-24 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
WO2005012508A1 (en) * | 2003-07-28 | 2005-02-10 | Queensland University Of Technology | Skin regeneration system |
JPWO2003097820A1 (en) * | 2002-05-22 | 2005-09-15 | 株式会社伏見製薬所 | Method for utilizing physiological activity of rare sugar and composition containing rare sugar |
WO2005113751A1 (en) * | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
EP1725656A1 (en) * | 2004-03-05 | 2006-11-29 | John E. Davies | Serum-free suspension culture system for mesenchymal progenitor cells |
EP1788076A1 (en) * | 2005-11-16 | 2007-05-23 | Cognis IP Management GmbH | Use of esters of unsaturated physiologically active fatty acids as nutrient media for cell cultures |
EP1820852A1 (en) * | 2004-11-19 | 2007-08-22 | JMS Co., Ltd. | Human serum for cell culture |
EP1881062A1 (en) * | 2005-05-09 | 2008-01-23 | Olympus Corporation | Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue |
EP1900810A1 (en) * | 2006-09-15 | 2008-03-19 | Celogos | Method of extracting and selecting cells |
EP1930413A1 (en) * | 2005-08-23 | 2008-06-11 | Oriental Yeast Co., Ltd. | Technique for culture of mesenchymal stem cell utilizing laminin-5 |
JP2008200520A (en) * | 2002-03-06 | 2008-09-04 | Univ Of Cincinnati | Surgical device for skin therapy or testing |
WO2008143884A2 (en) * | 2007-05-14 | 2008-11-27 | Cardiac Pacemakers, Inc. | Media and devices for cold storage of therapeutic cells |
WO2009030092A1 (en) * | 2007-09-05 | 2009-03-12 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof |
US7906330B2 (en) | 2001-12-07 | 2011-03-15 | Geron Corporation | Two cell population comprising chondrocyte precursors and human embryonic stem cells |
WO2011124894A1 (en) | 2010-04-08 | 2011-10-13 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
WO2013019661A1 (en) * | 2011-07-29 | 2013-02-07 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
WO2015061839A1 (en) * | 2013-11-04 | 2015-05-07 | Sturm Marian June | Cell culture method |
CN106459912A (en) * | 2014-11-14 | 2017-02-22 | 再生医科学股份有限公司 | Method for serum-free culture of cartilage cells and serum-free culture medium |
US9644182B2 (en) | 2001-04-24 | 2017-05-09 | Dolores Baksh | Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
WO2019072889A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | Perfusion medium |
WO2021158103A1 (en) * | 2020-02-03 | 2021-08-12 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell. |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2217031T3 (en) * | 1999-12-28 | 2004-11-01 | Iso Tis N.V. | CELL CULTURE MEDIA CONTAINING GROWTH FACTORS AND L-GLUTAMINE. |
US20070141036A1 (en) * | 2002-01-09 | 2007-06-21 | Alberto Gorrochategui Barrueta | Composition and procedure for tissue creation, regeneration and repair by a cell-bearing biological implant enriched with platelet concentrate and supplements |
US20050233446A1 (en) * | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
WO2005099758A2 (en) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Injectable bioartificial tissue matrix |
JP4219955B2 (en) * | 2004-07-06 | 2009-02-04 | 協和発酵キリン株式会社 | Method for producing nerve cells |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
JP4646600B2 (en) * | 2004-11-02 | 2011-03-09 | オリンパス株式会社 | Method for culturing mesenchymal stem cells |
JP2006136281A (en) * | 2004-11-15 | 2006-06-01 | Olympus Corp | Medium and method for culturing mesenchymal stem cell |
US20090169523A1 (en) | 2005-06-13 | 2009-07-02 | Catherine Verfaillie | Hsc self-renewal |
JP4921083B2 (en) * | 2005-09-13 | 2012-04-18 | タカラバイオ株式会社 | Serum-free medium for retrovirus production |
WO2007044418A2 (en) * | 2005-10-06 | 2007-04-19 | Moscatello David K | Cell culture media, kits and methods of use |
AU2007205522B2 (en) | 2006-01-13 | 2011-08-11 | Two Cells Co., Ltd. | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit |
ITTO20060282A1 (en) * | 2006-04-14 | 2007-10-15 | Univ Degli Studi Torino | MEDIUM OF CULTURE AND PHARMACEUTICAL COMPOSITION FOR THE REGENERATION OF THE RELATIVE PAPER FABRIC PROCEDURE RELATED TO USES AND PRODUCTS |
JP2009540826A (en) * | 2006-06-20 | 2009-11-26 | ジェンザイム・コーポレーション | Serum-free medium and its use for chondrocyte amplification |
JP2008099662A (en) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | Method for culturing stem cell |
US7951593B2 (en) * | 2007-03-20 | 2011-05-31 | Universite Rene Descartes-Paris V | Culture medium for gingival fibroblasts |
ITMI20071421A1 (en) * | 2007-07-16 | 2009-01-17 | Fond Irccs Istituto Di Ricove | CULTURE TO EXPAND EX-LIVE STEM CELLS |
SG187493A1 (en) | 2008-01-18 | 2013-02-28 | Univ Minnesota | Stem cell aggregates and methods for making and using |
US20100015710A1 (en) * | 2008-04-25 | 2010-01-21 | Sunghoon Jung | Methods and Compositions for Isolating, Maintaining and Serially Expanding Human Mesenchymal Stem Cells |
KR20180018839A (en) * | 2008-06-30 | 2018-02-21 | 얀센 바이오테크 인코포레이티드 | Differentiation of pluripotent stem cells |
US20110212523A1 (en) * | 2008-11-11 | 2011-09-01 | Yukio Kato | Differentiation-inducing culture medium additive and use thereof |
EP2456860B1 (en) | 2009-07-21 | 2018-09-05 | ABT Holding Company | Use of stem cells to reduce leukocyte extravasation |
AU2010276201B2 (en) | 2009-07-21 | 2013-10-17 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
SG177467A1 (en) * | 2009-07-23 | 2012-02-28 | Agency Science Tech & Res | Pre-natal mesenchymal stem cells |
CA2783437C (en) * | 2009-11-12 | 2020-08-04 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
SG10201501402UA (en) | 2010-02-25 | 2015-04-29 | Abt Holding Co | Modulation of macrophage activation |
BR112012021451B8 (en) | 2010-02-25 | 2021-05-25 | Abt Holding Co | use of cells that have a desired efficiency for expression and/or secretion of the pro-angiogenic factors vegf, cxcl5 and il8, methods to build a cell bank, to develop drug, and to increase the expression of one or more pro-angiogenic factors angiogenic in a cell performed in vitro, and composition |
AU2011225158C1 (en) | 2010-03-10 | 2014-01-23 | Two Cells Co., Ltd. | Cell preparation containing mesenchymal stem cells, and method for producing same |
SG185526A1 (en) | 2010-05-12 | 2012-12-28 | Abt Holding Co | Modulation of splenocytes in cell therapy |
WO2011158125A2 (en) | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
AU2011293440B2 (en) | 2010-08-24 | 2016-05-05 | Katholieke Universiteit Leuven | Non-static suspension culture of cell aggregates |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
EP2670842A2 (en) | 2011-01-31 | 2013-12-11 | Katholieke Universiteit Leuven KU Leuven Research & Development | Methods for making cells with an extra-embryonic endodermal precursor phenotype |
PL2718416T3 (en) | 2011-06-06 | 2020-05-18 | ReGenesys BVBA | Expansion of stem cells in hollow fiber bioreactors |
RU2461623C1 (en) * | 2011-06-20 | 2012-09-20 | Борис Карпович Гаврилюк | Method for cartilage cell culture |
JP2014526887A (en) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | How to improve the success rate of hematopoietic stem cell transplantation |
GB201119335D0 (en) | 2011-11-09 | 2011-12-21 | Univ Leuven Kath | Hepatitis virus infectable stem cells |
US9321995B2 (en) * | 2012-12-20 | 2016-04-26 | Suzhou Biowisetech Co., Ltd. | Stem cell culture medium and its applications as well as a stem cell culture method |
WO2014146057A2 (en) * | 2013-03-15 | 2014-09-18 | Cmr Technologies, Llc | Mesenchymal stem cells |
ES2827250T3 (en) | 2013-04-12 | 2021-05-20 | Houston Methodist Hospital | Improvement of organs for transplantation |
DK2992088T3 (en) | 2013-04-30 | 2019-11-11 | Univ Leuven Kath | CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES |
JP6512759B2 (en) * | 2013-08-19 | 2019-05-15 | 国立研究開発法人国立循環器病研究センター | Method of producing amniotic mesenchymal cell composition, method of cryopreservation, and therapeutic agent |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
CN103805562B (en) * | 2014-01-13 | 2015-08-05 | 章毅 | Cultivate the serum free medium of placenta mesenchyma stem cell |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
AU2015264043B2 (en) * | 2014-05-23 | 2020-08-13 | Regen Therapies, Inc. | Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts |
US9433629B2 (en) | 2014-05-23 | 2016-09-06 | Juan Paz Garcia | Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts |
US9669074B2 (en) * | 2014-05-23 | 2017-06-06 | Juan Paz Garcia | Formulation for regeneration of bone, cartilage, teeth, and periodontium and treatment of tumors and cysts |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
CN113957043A (en) * | 2015-03-04 | 2022-01-21 | 迈索布拉斯特国际有限公司 | Cell culture method of mesenchymal stem cells |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
SG11201806245TA (en) | 2016-01-21 | 2018-08-30 | Abt Holding Co | Stem cells for wound healing |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
SG11201900058YA (en) * | 2016-07-04 | 2019-02-27 | Agency Science Tech & Res | Method of generating mesenchymal stem cells and uses thereof |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
JP7372518B2 (en) * | 2019-06-27 | 2023-11-01 | 国立大学法人山口大学 | Method for culturing bone marrow-derived mesenchymal stem cells |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
WO1996039487A1 (en) * | 1995-06-05 | 1996-12-12 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
WO1996040866A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
WO1997033978A1 (en) * | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
WO1998004681A2 (en) * | 1996-07-25 | 1998-02-05 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
WO1998032333A1 (en) * | 1996-12-06 | 1998-07-30 | Osiris Therapeutics, Inc. | Improved chondrogenic differentiation of human mesenchymal stem cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
-
1999
- 1999-11-08 RU RU2001116126/13A patent/RU2272839C2/en not_active IP Right Cessation
- 1999-11-08 AU AU13804/00A patent/AU758073B2/en not_active Ceased
- 1999-11-08 EP EP99971844A patent/EP1131407B1/en not_active Expired - Lifetime
- 1999-11-08 IL IL14291499A patent/IL142914A0/en active IP Right Grant
- 1999-11-08 CA CA002348687A patent/CA2348687A1/en not_active Abandoned
- 1999-11-08 JP JP2000581163A patent/JP2002529071A/en active Pending
- 1999-11-08 US US09/831,161 patent/US6617159B1/en not_active Expired - Fee Related
- 1999-11-08 DE DE69933579T patent/DE69933579D1/en not_active Expired - Fee Related
- 1999-11-08 WO PCT/EP1999/008482 patent/WO2000027996A1/en active IP Right Grant
- 1999-11-08 AT AT99971844T patent/ATE342348T1/en not_active IP Right Cessation
-
2001
- 2001-05-01 IL IL142914A patent/IL142914A/en not_active IP Right Cessation
-
2003
- 2003-07-08 US US10/614,191 patent/US7109032B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
WO1996039487A1 (en) * | 1995-06-05 | 1996-12-12 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
WO1996040866A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
WO1997033978A1 (en) * | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
WO1998004681A2 (en) * | 1996-07-25 | 1998-02-05 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
WO1998032333A1 (en) * | 1996-12-06 | 1998-07-30 | Osiris Therapeutics, Inc. | Improved chondrogenic differentiation of human mesenchymal stem cells |
Non-Patent Citations (2)
Title |
---|
PAIN B ET AL: "LONG-TERM IN VITRO CULTURE AND CHARACTERISATION OF AVIAN EMBRYONIC STEM CELLS WITH MULTIPLE MORPHOGENETIC POTENTIALITIES", DEVELOPMENT,GB,COLCHESTER, ESSEX, vol. 122, August 1996 (1996-08-01), pages 2239 - 2248, XP002913043, ISSN: 0950-1991 * |
QUARTO R ET AL: "Proliferation and differentiation of chondrocytes in defined culture medium: effects of systemic factors", BONE, vol. 17, no. 6, December 1995 (1995-12-01), pages 558, XP000891633 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9644182B2 (en) | 2001-04-24 | 2017-05-09 | Dolores Baksh | Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
WO2003013464A1 (en) * | 2001-08-10 | 2003-02-20 | L'oreal | Composition comprising an association between igf1 and the ascorbic acid |
FR2828401A1 (en) * | 2001-08-10 | 2003-02-14 | Oreal | Cosmetic composition useful for improving skin condition comprises insulin-like growth of specific factor or it's mimetic and ascorbic acid |
JP2003052360A (en) * | 2001-08-20 | 2003-02-25 | Japan Science & Technology Corp | Method for culturing mesenchymal stem cell using extracellular substrate of basement membrane cell |
US7906330B2 (en) | 2001-12-07 | 2011-03-15 | Geron Corporation | Two cell population comprising chondrocyte precursors and human embryonic stem cells |
US8546101B2 (en) | 2001-12-07 | 2013-10-01 | Geron Corporation | Compound screening using chondrocytes derived from primate pluripotent stem cells |
EP1478734A4 (en) * | 2002-01-25 | 2006-04-05 | Genzyme Corp | Serum-free media for chondrocytes and methods of use thereof |
EP1478734A2 (en) * | 2002-01-25 | 2004-11-24 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
US7169610B2 (en) | 2002-01-25 | 2007-01-30 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
US8765468B2 (en) | 2002-03-06 | 2014-07-01 | University Of Cincinnati | Surgical device for skin therapy or testing |
JP2008200520A (en) * | 2002-03-06 | 2008-09-04 | Univ Of Cincinnati | Surgical device for skin therapy or testing |
US8450108B2 (en) | 2002-03-06 | 2013-05-28 | University Of Cincinnati | Surgical device for skin therapy or testing |
US9089417B2 (en) | 2002-03-06 | 2015-07-28 | Steven T. Boyce | Surgical device for skin therapy or testing |
JP4554940B2 (en) * | 2002-04-03 | 2010-09-29 | 直秀 山下 | Medicament containing mesenchymal cells derived from human placenta and method for producing VEGF using the cells |
WO2003082305A1 (en) * | 2002-04-03 | 2003-10-09 | Naohide Yamashita | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells |
JPWO2003082305A1 (en) * | 2002-04-03 | 2005-07-28 | 直秀 山下 | Medicament containing mesenchymal cells derived from human placenta and method for producing VEGF using the cells |
JPWO2003097820A1 (en) * | 2002-05-22 | 2005-09-15 | 株式会社伏見製薬所 | Method for utilizing physiological activity of rare sugar and composition containing rare sugar |
WO2004083415A1 (en) * | 2003-03-17 | 2004-09-30 | Biotissue Technologies Gmbh | Cartilaginous cell culture medium and the use thereof |
WO2005012508A1 (en) * | 2003-07-28 | 2005-02-10 | Queensland University Of Technology | Skin regeneration system |
US8911997B2 (en) | 2003-07-28 | 2014-12-16 | Queensland University Of Technology | Mammalian cell culture medium |
EP1725656A1 (en) * | 2004-03-05 | 2006-11-29 | John E. Davies | Serum-free suspension culture system for mesenchymal progenitor cells |
EP1725656A4 (en) * | 2004-03-05 | 2007-10-03 | John E Davies | Serum-free suspension culture system for mesenchymal progenitor cells |
WO2005113751A1 (en) * | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
EP1820852A1 (en) * | 2004-11-19 | 2007-08-22 | JMS Co., Ltd. | Human serum for cell culture |
EP1820852A4 (en) * | 2004-11-19 | 2007-11-14 | Jms Co Ltd | Human serum for cell culture |
US8679838B2 (en) | 2004-11-19 | 2014-03-25 | Jms Co., Ltd. | Human serum for cell culture |
US7972767B2 (en) | 2005-05-09 | 2011-07-05 | Olympus Corporation | Method for culturing mesenchymal stem cell and method for producing biological tissue prosthesis |
EP1881062A4 (en) * | 2005-05-09 | 2009-03-11 | Olympus Corp | Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue |
EP1881062A1 (en) * | 2005-05-09 | 2008-01-23 | Olympus Corporation | Culture method for mesenchymal stem cell and process for production of supporting material for biological tissue |
EP1930413A1 (en) * | 2005-08-23 | 2008-06-11 | Oriental Yeast Co., Ltd. | Technique for culture of mesenchymal stem cell utilizing laminin-5 |
US8728814B2 (en) | 2005-08-23 | 2014-05-20 | Oriental Yeast Co., Ltd. | Technique for culture of mesenchymal stem cell utilizing laminin-5 |
EP1930413A4 (en) * | 2005-08-23 | 2008-12-17 | Oriental Yeast Co Ltd | Technique for culture of mesenchymal stem cell utilizing laminin-5 |
EP1788076A1 (en) * | 2005-11-16 | 2007-05-23 | Cognis IP Management GmbH | Use of esters of unsaturated physiologically active fatty acids as nutrient media for cell cultures |
WO2008031957A3 (en) * | 2006-09-15 | 2008-07-03 | Celogos | Method for extracting and selecting cells |
EP1900810A1 (en) * | 2006-09-15 | 2008-03-19 | Celogos | Method of extracting and selecting cells |
WO2008031957A2 (en) * | 2006-09-15 | 2008-03-20 | Celogos | Method for extracting and selecting cells |
WO2008143884A3 (en) * | 2007-05-14 | 2009-09-03 | Cardiac Pacemakers, Inc. | Media and devices for cold storage of therapeutic cells |
WO2008143884A2 (en) * | 2007-05-14 | 2008-11-27 | Cardiac Pacemakers, Inc. | Media and devices for cold storage of therapeutic cells |
US8114668B2 (en) | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
WO2009030092A1 (en) * | 2007-09-05 | 2009-03-12 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof |
WO2011124894A1 (en) | 2010-04-08 | 2011-10-13 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
US9029145B2 (en) | 2010-04-08 | 2015-05-12 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
US9725697B2 (en) | 2010-04-08 | 2017-08-08 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
WO2013019661A1 (en) * | 2011-07-29 | 2013-02-07 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
US9034584B2 (en) | 2011-07-29 | 2015-05-19 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
WO2015061839A1 (en) * | 2013-11-04 | 2015-05-07 | Sturm Marian June | Cell culture method |
AU2014344795B2 (en) * | 2013-11-04 | 2016-05-26 | Isopogen Pty Ltd | Cell culture method |
US9868936B2 (en) | 2013-11-04 | 2018-01-16 | Isopogen Pty Ltd | Cell culture method |
US11041144B2 (en) | 2013-11-04 | 2021-06-22 | Isopogen Pty Ltd | Cell culture method |
CN106459912A (en) * | 2014-11-14 | 2017-02-22 | 再生医科学股份有限公司 | Method for serum-free culture of cartilage cells and serum-free culture medium |
EP3219792A4 (en) * | 2014-11-14 | 2018-04-11 | Regenesis Science Co. Ltd. | Method for serum-free culture of cartilage cells and serum-free culture medium |
EP3536778A1 (en) * | 2014-11-14 | 2019-09-11 | Regenesis Science Co. Ltd. | Method for serum-free culture of chondrocytes and serum-free culture medium |
CN106459912B (en) * | 2014-11-14 | 2021-05-25 | 再生医科学股份有限公司 | Serum-free culture method and serum-free culture medium for chondrocytes |
US11427808B2 (en) | 2014-11-14 | 2022-08-30 | Regenesis Science Co., Ltd. | Method for serum-free culture of chondrocytes and serum-free culture medium |
WO2019072889A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | Perfusion medium |
WO2021158103A1 (en) * | 2020-02-03 | 2021-08-12 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell. |
Also Published As
Publication number | Publication date |
---|---|
AU758073B2 (en) | 2003-03-13 |
US7109032B2 (en) | 2006-09-19 |
IL142914A0 (en) | 2002-04-21 |
EP1131407A1 (en) | 2001-09-12 |
DE69933579D1 (en) | 2006-11-23 |
JP2002529071A (en) | 2002-09-10 |
CA2348687A1 (en) | 2000-05-18 |
EP1131407B1 (en) | 2006-10-11 |
AU1380400A (en) | 2000-05-29 |
US6617159B1 (en) | 2003-09-09 |
RU2272839C2 (en) | 2006-03-27 |
US20050090002A1 (en) | 2005-04-28 |
IL142914A (en) | 2006-07-05 |
ATE342348T1 (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU758073B2 (en) | Serum free medium for chondrocyte-like cells | |
EP1988159B1 (en) | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit | |
US6709864B1 (en) | Adipogenic differentiation of human mesenchymal stem cells | |
EP1018987B1 (en) | Neocartilage and methods of use | |
US6730314B2 (en) | Culturing encapsulated chondrocytes under reduced oxygen partial pressure to produce cartilage implants | |
CN101412985A (en) | Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells | |
US20080187518A1 (en) | Production of Osteoclasts from Adipose Tissues | |
WO2021254296A1 (en) | Bioactive substance composition, serum-free culture medium comprising the composition, and uses thereof | |
US20230117670A1 (en) | Bioactive substance composition, serum-free medium comprising the composition, and uses thereof | |
US11840706B2 (en) | Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells | |
CANALIS et al. | Effect of partially purified bone morphogenetic protein on DNA synthesis and cell replication in calvarial and fibroblast cultures. | |
Hendriks et al. | Effect of stratified culture compared to confluent culture in monolayer on proliferation and differentiation of human articular chondrocytes | |
O'Keefe et al. | Countercurrent centrifugal elutriation. High-resolution method for the separation of growth-plate chondrocytes. | |
KR101503939B1 (en) | Method for preparation of cartilage cell | |
KR100394430B1 (en) | Medium for culturing human cell comprising human serum and method for culturing human cell using same | |
SHIMOMURA et al. | Cultured growth cartilage cells. | |
JP2007000077A (en) | Method for serum-free culture of adherent animal cell and culture medium for serum-free culture of adherent animal cell | |
US20070004037A1 (en) | Methods and compositions for culturing keratinocytes | |
Suryawan et al. | The primary cell culture system for preadipocytes | |
Zamani et al. | Comparison of cartilage specific markers in articular and differentiated chondrocytes in pellet system. | |
CN112410296A (en) | Serum-free cell culture medium | |
Collodi et al. | Serum-free media | |
MXPA97005612A (en) | Induction directed by lineage of the differentiation of human mesenquimatosas cells of ori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2000 13804 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2348687 Country of ref document: CA Kind code of ref document: A Ref document number: 2348687 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142914 Country of ref document: IL Ref document number: 13804/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999971844 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2000 581163 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09831161 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971844 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 13804/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999971844 Country of ref document: EP |